Back

Time-to-retraction and likelihood of evidence contamination (VITALITY Extension I): a retrospective cohort analysis

Yuan, Y.; Peng, Z.; Doi, S. A. R.; Furuya-Kanamori, L.; Cao, H.; Lin, L.; Chu, H.; Loke, Y.; Mol, B. W.; Golder, S.; Vohra, S.; Xu, C.

2026-02-24 epidemiology
10.64898/2026.02.20.26346631 medRxiv
Show abstract

BackgroundThe number of problematic randomized clinical trials (RCTs) has risen sharply in recent decades, posing serious challenges to the integrity of the healthcare evidence ecosystem. ObjectiveTo investigate whether retraction of problematic RCTs could reduce evidence contamination. DesignRetrospective cohort study SettingA secondary analysis of the VITALITY Study database. Participants1,330 retracted RCTs with 847 systematic reviews. MeasurementsThe difference in the median number (and its interquartile, IQR) of contamination before and after retraction. The association between time-to-retraction and likelihood of evidence contamination. ResultsAmong these retracted RCTs, 426 led to evidence contamination, resulting in 1,106 contamination events (251 after retraction vs. 855 before retraction). The time interval between RCT publication and first contamination ranged from 0.2 to 30.9 years, with a median of 3.3 years (95% CI: 3.0 to 3.9). The median number of contaminated systematic reviews was lower after retraction than before retraction (0, IQR: 0 to 1 vs. 1, IQR: 1 to 2, P < 0.01). Compared with trials retracted more than 7.5 years after publication, those retracted between 1.0 and 1.8 years (OR = 0.70, 95% CI: 0.60 to 0.80) and retracted within 1.0 year (OR = 0.69, 95% CI: 0.60 to 0.80) were associated with lower likelihood of evidence contamination. LimitationsOnly assessed contaminated systematic reviews with quantitative synthesis and limited to retracted RCTs. ConclusionsRetracting problematic RCTs can significantly reduce evidence contamination, and faster retraction was associated with less contamination. To safeguard the integrity of the evidence ecosystem, academic journals should act promptly in the retraction of problematic studies to minimize their downstream impact. Primary Funding SourcesThe National Natural Science Foundation of China (72204003, 72574229)

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Journal of Clinical Epidemiology
28 papers in training set
Top 0.1%
23.7%
2
BMC Medicine
163 papers in training set
Top 0.1%
11.0%
3
Research Synthesis Methods
20 papers in training set
Top 0.1%
8.8%
4
PLOS ONE
4510 papers in training set
Top 30%
5.1%
5
Nature Human Behaviour
85 papers in training set
Top 0.5%
5.1%
50% of probability mass above
6
BMJ Open
554 papers in training set
Top 4%
5.1%
7
PLOS Medicine
98 papers in training set
Top 0.7%
4.5%
8
PLOS Biology
408 papers in training set
Top 5%
2.9%
9
Pharmacoepidemiology and Drug Safety
13 papers in training set
Top 0.1%
2.9%
10
Nature Communications
4913 papers in training set
Top 46%
2.2%
11
Medicine
30 papers in training set
Top 0.8%
2.2%
12
JAMA Network Open
127 papers in training set
Top 2%
1.6%
13
Systematic Reviews
11 papers in training set
Top 0.2%
1.6%
14
BMJ
49 papers in training set
Top 0.8%
1.3%
15
International Journal of Epidemiology
74 papers in training set
Top 2%
0.9%
16
Trials
25 papers in training set
Top 1%
0.9%
17
BMC Medical Research Methodology
43 papers in training set
Top 1%
0.9%
18
The Lancet Infectious Diseases
71 papers in training set
Top 2%
0.9%
19
JAMA
17 papers in training set
Top 0.2%
0.8%
20
Healthcare
16 papers in training set
Top 2%
0.8%
21
Journal of the American Medical Informatics Association
61 papers in training set
Top 2%
0.8%
22
eLife
5422 papers in training set
Top 60%
0.7%
23
Scientific Reports
3102 papers in training set
Top 77%
0.7%
24
The Lancet Global Health
24 papers in training set
Top 1%
0.5%
25
Clinical Microbiology and Infection
60 papers in training set
Top 2%
0.5%